SIGA Technologies — Onwards and upwards with strong FY23

SIGA Technologies (NASDAQ: SIGA)

Last close As at 24/06/2024

USD7.08

0.42 (6.31%)

Market capitalisation

USD504m

More on this equity

Research: Healthcare

SIGA Technologies — Onwards and upwards with strong FY23

SIGA Technologies has delivered its best top-line performance in the last five years, supported by a late surge in TPOXX deliveries across both domestic and international markets. FY23 product revenues grew 50.8% to $130.7m, driven by Q423 BARDA deliveries and international orders, resulting in overall revenues increasing to $139.9m (+26.3% y-o-y). Barring packaging-related bottlenecks, which delayed some deliveries to Q124, there could have been incremental upside to meet our $172.6m revenue estimate. The strong cash flow generation and healthy balance sheet (year-end net cash balance of $150.1m) was reflected in the company’s declaration of a special cash dividend of $0.6/share ($42.7m total; >60% payout ratio). Given sales visibility on further BARDA stockpile replenishments and increasing international market traction, we expect FY24 to be another strong year. We revise our FY24 estimates and now expect PEP and pediatric launches in 2026 (2025 previously), resulting in our valuation adjusting to $16.51/share (versus $17.24/share previously).

Soo Romanoff

Written by

Soo Romanoff

Managing Director - Head of Content, Healthcare

Healthcare

SIGA Technologies

Onwards and upwards with strong FY23

FY23 results update

Pharma and biotech

18 March 2024

Price

US$7.33

Market cap

US$521m

Net cash (US$m) at 31 December 2023

150.1

Shares in issue

71.1m

Free float

56%

Code

SIGA

Primary exchange

Nasdaq

Secondary exchange

N/A

Share price performance

%

1m

3m

12m

Abs

42.3

31.8

30.4

Rel (local)

39.9

21.6

(0.8)

52-week high/low

US$7.3

US$4.3

Business description

SIGA Technologies is a commercial-stage health security company focused on the treatment of smallpox and other orthopoxvirus. It has contracts with both the US and Canadian governments for TPOXX, its treatment for smallpox, and is expanding internationally.

Next events

Q124 results

May 2024

Analysts

Soo Romanoff

+44 (0)20 3077 5700

Jyoti Prakash, CFA

+44 (0)20 3077 5700

Jitisha Malhotra

+44 (0)20 3077 5700

SIGA Technologies is a research client of Edison Investment Research Limited

SIGA Technologies has delivered its best top-line performance in the last five years, supported by a late surge in TPOXX deliveries across both domestic and international markets. FY23 product revenues grew 50.8% to $130.7m, driven by Q423 BARDA deliveries and international orders, resulting in overall revenues increasing to $139.9m (+26.3% y-o-y). Barring packaging-related bottlenecks, which delayed some deliveries to Q124, there could have been incremental upside to meet our $172.6m revenue estimate. The strong cash flow generation and healthy balance sheet (year-end net cash balance of $150.1m) was reflected in the company’s declaration of a special cash dividend of $0.6/share ($42.7m total; >60% payout ratio). Given sales visibility on further BARDA stockpile replenishments and increasing international market traction, we expect FY24 to be another strong year. We revise our FY24 estimates and now expect PEP and pediatric launches in 2026 (2025 previously), resulting in our valuation adjusting to $16.51/share (versus $17.24/share previously).

Year end

Revenue
(US$m)

EBITDA*
(US$m)

PBT*
(US$m)

EPS*
(US$)

P/E
(x)

Net cash
(US$m)

12/22

110.8

43.2

43.7

0.46

15.9

98.8

12/23

139.9

84.2

87.8

0.95

7.7

150.1

12/24e

190.6

104.4

108.4

1.18

6.2

166.6

12/25e

169.3

96.3

100.7

1.10

6.7

192.3

Note: *EBITDA, PBT and EPS (basic) are normalized, excluding amortization of acquired intangibles, exceptional items and share-based payments.

A rewarding end to FY23

SIGA’s top-line performance was weighted to Q4, with deliveries to the US strategic national stockpile ($97.9m of the $112.5m order for oral TPOXX) and HERA ($12m of the $18m order) driving the full-year performance. Previously flagged packaging-related issues delayed some deliveries, although we understand that these have largely been fulfilled in Q124, with the exception of the c $15m IV TPOXX deliveries previously planned for Q423. We expect all pending deliveries to be made in FY24, in addition to the expected $112.5m in oral TPOXX (assuming this final option is exercised by BARDA) and remaining IV TPOXX deliveries from the August 2022 order. Traction in international market orders could potentially add further upside.

PEP sNDA anticipated in the next 12 months

SIGA maintains its plans to pursue the PEP label expansion opportunity, supported by data provided by the Centers for Disease Control and Prevention (CDC) on the Jynneos+TPOXX sample subset shared with the agency). SIGA now plans to re-analyze all samples for a supplementary new drug application (sNDA) expected within the next 12 months. We continue to view the label expansion as a key future value driver for SIGA, but, as a conservative measure, we have pushed out our launch timelines to 2026 (versus 2025 previously).

Valuation: Adjusts to $16.51 per share

We adjust our valuation for SIGA to $1.17bn or $16.51/share, from $1.23bn or $17.24/share, largely due to the revised launch timelines for the PEP and pediatric label expansions (2026 from 2025). We also incorporate the latest net cash figure and the announced dividend payout.

Another strong year for the books

FY23 was another strong year for SIGA, with the company recording its best top-line performance in the last five years, driven by the strong order book ($164m worth of new orders during the year), including material stockpile deliveries to the Biomedical Advanced Research and Development Authority (BARDA) and further supported by an $18m order from the European Health Emergency Preparedness and Response Authority (HERA). Despite packaging-related bottlenecks hampering deliveries, the company was able to deliver $115.7m worth of orders (c 77% of the planned $151m worth of deliveries). Of the pending deliveries, $22m have since been made in January and February 2024. According to our understanding, the $15m in IV TPOXX deliveries planned for Q423 remain outstanding. Given the strong operating performance, SIGA has announced a special dividend of $0.6/share, marking a third consecutive year of dividend payouts. There were no share buybacks in Q423 and, with the conclusion of the ongoing share repurchase program (as at 31 December 2023), we assume the company will put greater focus on dividend payouts as a means of rewarding shareholders. For FY24, we expect the stockpile deliveries of oral and IV TPOXX to BARDA to drive top-line momentum, with upside optionality from growth in international orders. In the longer term, we expect the potential PEP and pediatric label expansions to support growth.

PEP label expansion sNDA expected in next 12 months

In FY23, SIGA successfully completed all clinical trial-related activities related to the PEP label expansion. While the expanded safety study was successfully concluded in Q123 and did not indicate any drug-related serious adverse events, the preliminary analysis of the immunogenicity trial (testing TPOXX plus JYNNEOS, an FDA-approved smallpox vaccine) did not reveal any meaningful differences in immunogenicity between the two groups (JYNNEOS + placebo group and JYNNEOS + TPOXX group). Subsequent observations indicated that the measurable immune response to the JYNNEOS vaccine in both groups was lower than expected, which could potentially prevent non-inferior statistical determination from being the primary endpoint of the study as originally planned.

SIGA thereafter arranged for some JYNNEOS + TPOXX samples to be tested by the CDC, which, encouragingly, demonstrated the expected immune response to the vaccine. The company is now working towards getting all samples re-analyzed. In parallel, it aims to submit an sNDA in the next 12 months (previously 2024). Based on these updates, we have conservatively pushed out the launch timeline under the PEP label to 2026, versus 2025 previously. We recognize that the US government can decide to stockpile the drug before FDA approval, but we conservatively assume that the authorities will wait until approval of the PEP indication. We continue to view the PEP label expansion as a key growth driver for SIGA, given that the indication calls for a longer treatment course (28 days versus 14 days of oral TPOXX) and therefore offers the potential to double the market opportunity in the United States for the company.

Mpox remains in focus

SIGA provided an update on the mpox clinical trial progress involving TPOXX in the FY23 earnings call. Despite a declining number of mpox cases across the globe, the company continues to enroll patients in its trials and collect data for its studies, indicating continued accumulation of case counts, especially in Africa. Key updates on the clinical trials include:

Democratic Republic of the Congo (DRC) – PALM 007 trial: successful enrolment of 425 patients in the trial as of February 2024 (vs 314 patients as of October 2023). It is sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), and Institut National de Recherche Biomédicale, with a target enrolment of over 450 participants.

United States: STOMP (A5418) trial: successful enrolment of 267 patients in the trial as of February 2024 (vs 157 patients as of October 2023). It is sponsored by the NIAID and targets enrolment of over 500 participants, including children and women who are pregnant or breastfeeding.

As a reminder, SIGA is coordinating with government sponsors in running four randomized controlled trials as well as multiple observation studies, to secure TPOXX’s approval for mpox in the United States. We note that TPOXX is already approved for treatment of all orthopoxvirus pathogens, including mpox in both the UK (July 2022) and the European Union (January 2022).

Financials

Strong operating performance…

SIGA’s Q423 revenues came in at $116.5m, comprising $115.7m in product sales and another $0.7m in R&D-related revenue. The product sales include $97.9m from oral TPOXX deliveries to the US Strategic National Stockpile (SNS), $6.0m in deliveries to the US Department of Defense (DoD) and $12.0m in international sales. FY23 total revenue stood at $139.9m, up 26.3% y-o-y, driven by a significant growth in product sales (of 50.8% y-o-y to $130.7m), which includes oral TPOXX deliveries to the US SNS ($97.9m), DoD ($10.6m) and international jurisdictions ($21.3m). Growth in product sales was somewhat offset by lower R&D revenues ($9.2m vs $24.1m in FY22), attributed to reduced clinical activity under the government-sponsored PEP label expansion study. Note that while the recorded product revenues were lower than our estimate of $163.7m, the company had previously alluded to the possibility of a slight delay in deliveries due to certain packaging related issues (most pending deliveries have been made in Q124 with the exception of the $15m of IV TPOXX deliveries that had been anticipated in Q423) and was therefore not entirely unexpected. Management has indicated that the company continues to work on normalizing these manufacturing bottlenecks.

Gross profit margin on product sales for the period was reported at 86% in FY23 (gross profit of $112.8m) versus 88% in FY22 ($76.2m in gross profit), primarily reflecting an increase in the manufacturing and delivery costs of oral TPOXX sold to the US government and other international countries. We note, however, that the margins were supported by the delay in delivery of IV TPOXX, which is a lower-margin product versus oral TPOXX (gross margin of less than 40% vs 85% for oral TPOXX). R&D expenses declined by 27.1% y-o-y to $16.4m. This drop was attributed to lower vendor-related expenses in relation to clinical activities for the PEP label expansion study and BARDA contract, partially offset by higher regulatory fees related to the EMA regulatory submissions. Despite an increase in professional fees, SG&A expenses during the year ($22.0m) were significantly lower than the $35.1m recorded in FY22, primarily reflecting a decline in the promotion fees to Meridian as international sales declined from $71m in FY22 to $21m in FY23. Overall SIGA reported a 95.8% yoy increase in its FY23 operating profit (to $83.6m). We note that this was below the company guided figure of $90–100m, which can primarily be attributed to the delay in some TPOXX deliveries due to packaging issues, which appear to be temporary in nature. Net income stood at $68.1m versus $33.9m in FY22.

… has prompted another special dividend announcement

SIGA’s strong operating performance has resulted in improving cash flows, with the company reporting operating cash flow of $94.8m (more than double the FY22 figure of $41.6m) and a period-end net cash figure of $150.1m (SIGA remains debt-free). This triggered the company to announce a special cash dividend of $0.6/share, to be paid out in April 2024. At the current outstanding share count of 71.1m, this comes to a payout of $42.7m and translates to a solid 11% dividend yield and a payout ratio of more than 60% of FY23 net income of $68.1m. As a reminder, the company had also declared a special dividend of $0.45/share in May 2023 and a similar dividend payout in May 2022, highlighting sustained business strength. With the balance sheet forecast to remain healthy in FY24, we think this trend is likely to continue (albeit it is not assured), which should support investor sentiment.

Estimates revision

Based on the Q423 results and improved visibility on deliveries related to contractual obligations, we have made some adjustments to our forecasts. We have revised our FY24 revenue estimate to $190.6m, from our previous forecast of $177.3m, primarily driven by some of the anticipated deliveries in Q423 rolling into 2024 on account of the aforementioned packaging-related issues. This includes $15m in oral TPOXX deliveries as part of the $112.5m due under the BARDA agreement, $6m under the $18m HERA agreement and $15m in IV TPOXX under the July 2022 agreement ($26m in IV TPOXX deliveries). We note that while the oral TPOXX deliveries to the SNS and HERA countries were made in January and February 2024, IV TPOXX deliveries remain outstanding ($20.8m in deferred revenue recognized as a liability in the balance sheet). We expect this to be delivered in 2024. In addition, we also expect BARDA to exercise the remaining $112.5m oral TPOXX option, which continues to be the primary driver of our top-line forecasts for FY24. We assume the entire oral TPOXX order and the $26m August 2022 IV TPOXX order will be delivered in FY24, along with $15m in IV TPOXX from the July 2023 order of $25m. Note that given the lower IV TPOXX margins, SIGA’s primary focus will likely continue to be on oral delivery and therefore our assumption for IV TPOXX deliveries is subject to revision. In terms of international orders, the Canada Department of National Defence holds an option to purchase up to $6.7m of oral TPOXX by December 2025, of which $0.7m of order was delivered in February 2024. We estimate another $3m will be exercised and delivered in FY24, with the remainder in FY25. Our FY25 estimates assume that SIGA will be able to sign a follow-up or new rolling agreement with BARDA for oral TPOXX and incorporate a $103m revenue contribution for the year. It also incorporates c $29m in international deliveries. However, we note that there is a high degree of variability and uncertainty in our assumptions and therefore these figures are subject to change as new information is made available. Exhibit 1 presents a breakdown of our product revenue estimates for FY24 and FY25.

Exhibit 1: Expected value of order deliveries in FY24 and FY25

US$m

FY24e (old)

FY24e (new)

FY25e

Domestic (US)

US BARDA contract – Oral

112.6

127.2

103.0

US BARDA contract – IV

26.0

41.0

35.6

US Department of Defense

0.5

1.0

0.0

Pediatric formulation

0.0

0.0

0.0

PEP label

0.0

0.0

0.0

International

Canada

– Military revenues

6.0

3.7

8.6

– Canada PHAC

7.5

3.5

6.1

EU, Australia, Japan*

14.0

12.4

13.9

Total deliveries (product revenue)

166.6

188.8

167.1

Source: Edison Investment Research. Note: *Adjusted for respective probabilities of success.

Following the receipt of the final payment under the PEP research contract with the DoD in Q323, we reduce our estimate for FY24 R&D related revenue to $1.9m from $10.7m previously. The corresponding figure for FY25 stands at $2.2m.

We make minor tweaks to our operating expense estimates, reflecting the FY23 trend and run rate. For FY24, we have increased our COGS estimate to $44.9m from $34.0m previously, given the higher proportion of IV TPOXX in the revenue we now assume. We also increase our SG&A expense estimate to $28.7m from $24.3m previously, anticipating a greater sales push in international markets. On the other hand, we lower our R&D estimate to $13.1m ($20.5m previously) to reflect the lower than anticipated research-related expenses in FY23 and slower anticipated activity in FY24. Our revised FY24 operating profit estimate stands at $103.9m ($98.5m previously). For FY25 we estimate an operating profit of $96.3m.

Valuation

We continue to value SIGA on a risk-adjusted net present value (rNPV) basis for its various programs and contracts, forecasting to the end of the patent life in each geography. Reflecting the discussed changes to our estimates, rolling forward our model (which gets us closer to patent expiry) and incorporating the new net cash figure has resulted in our valuation adjusting to $1.17bn or $16.51/share, from $1.23bn or $17.24/share previously. The key changes to our valuation are the revised launch timelines for the PEP and pediatric label expansions (2026 from 2025 previously) and a slower ramp-up in mpox sales than previously projected. Our revised valuation is presented in Exhibit 2.

Exhibit 2: SIGA’s valuation

Product/program

Main indication

Status

Probability of success

Approval/launch/
first contract year

Peak sales ($m)

rNPV
($m)

TPOXX (US base – Oral)

Treatment of smallpox

On market

100%

2018

128

314

TPOXX (Canada)

Treatment of smallpox

On market

100%

2020

15

35

TPOXX US IV and pediatric formulations

Treatment of smallpox

IV (NDA approved May 2022), pediatric (being formulated)

50–100%

2022–26

45

33

TPOXX US PEP

Post-exposure prophylaxis following exposure to smallpox

Development

50%

2026

126

219

TPOXX EU, Japan, Korea, Australia

Treatment of smallpox

EMA approved

55%

2022

279

227

Commercialization of TPOXX, PEP. US, Canada, Europe, Asia

Treatment of mpox

2025

104

195

Total

 

 

 

 

 

1,024

Net cash (Q423) ($m)

150.1

Total firm value ($m)

1,174

Total basic shares (m) outstanding

71.1

Value per basic share ($)

$16.51

Source: Edison Investment Research


Exhibit 3: Financial summary

US$000s

2022

2023

2024e

2025e

Year end 31 December

US GAAP

US GAAP

US GAAP

US GAAP

PROFIT & LOSS

 

 

 

Revenue

 

 

110,776

139,917

190,611

169,336

Of which Product revenue

86,662

130,668

188,761

167,116

Of which R&D revenue

24,114

9,249

1,850

2,220

Cost of Sales

(10,433)

(17,825)

(44,872)

(33,871)

Gross Profit on product sales

76,229

112,843

143,890

133,244

Research & Development

(22,526)

(16,428)

(13,142)

(13,274)

General & Administrative

(35,117)

(22,043)

(28,686)

(26,440)

EBITDA

 

 

43,218

84,159

104,449

96,288

Operating Profit (before amort. and excepts.)

 

 

42,700

83,621

103,911

95,750

Net Interest

1,032

4,156

4,504

4,998

Exceptionals

401

-

-

-

Profit Before Tax (norm)

 

 

43,732

87,777

108,415

100,748

Profit Before Tax (reported)

 

 

44,133

87,777

108,415

100,748

Tax

(10,228)

(19,708)

(24,342)

(22,620)

Deferred tax

-

-

-

-

Profit After Tax (norm)

33,504

68,069

84,074

78,128

Profit After Tax (reported)

33,905

68,069

84,074

78,128

Average Number of Shares Outstanding (m)

73

71

71

71

EPS - normalized ($), basic

 

 

0.46

0.95

1.18

1.10

EPS - normalised fully diluted ($)

 

 

0.46

0.95

1.22

1.19

EPS - reported ($)

 

 

0.46

0.95

1.18

1.10

Gross Margin (%)

88

86

76

80

EBITDA Margin (%)

39

60

55

57

Operating Margin (before GW and except.) (%)

39

60

55

57

BALANCE SHEET

Fixed Assets

 

 

9,250

15,362

14,845

14,328

Intangible Assets

898

898

898

898

Tangible Assets

1,848

1,332

815

298

Other

6,503

13,132

13,132

13,132

Current Assets

 

 

185,786

238,991

262,317

293,170

Stocks

39,273

64,218

67,429

70,801

Debtors

45,407

21,131

23,244

25,568

Cash

98,791

150,146

166,594

192,329

Other

2,316

3,496

5,050

4,471

Current Liabilities

 

 

(21,518)

(54,118)

(33,456)

(33,376)

Creditors

(3,355)

(1,456)

(1,583)

(1,503)

Short term borrowings

-

-

-

-

Other

(18,162)

(52,661)

(31,873)

(31,873)

Long Term Liabilities

 

 

(3,358)

(3,376)

(3,376)

(3,376)

Long term borrowings

-

-

-

-

Other long term liabilities

(3,358)

(3,376)

(3,376)

(3,376)

Net Assets

 

 

170,160

196,859

240,330

270,746

Minority Interests

-

-

-

-

Shareholder equity

 

 

170,160

196,859

240,330

270,746

CASH FLOW

Operating Cash Flow

 

 

41,611

94,799

59,124

75,522

Capex

-

(22)

(22)

(22)

Acquisitions/disposals

-

-

-

-

Financing

-

-

-

-

Dividends

(32,940)

(32,135)

(42,655)

(49,764)

Other (including share buybacks)

(13,019)

(11,287)

-

-

Net Cash Flow

(4,348)

51,355

16,448

25,736

Opening net debt/(cash)

 

 

(103,139)

(98,791)

(150,146)

(166,594)

Exchange rate movements

-

-

-

-

Other

-

-

-

-

Closing net debt/(cash)

 

 

(98,791)

(150,146)

(166,594)

(192,329)

Source: Company reports, Edison Investment Research

General disclaimer and copyright

This report has been commissioned by SIGA Technologies and prepared and issued by Edison, in consideration of a fee payable by SIGA Technologies. Edison Investment Research standard fees are £60,000 pa for the production and broad dissemination of a detailed note (Outlook) following by regular (typically quarterly) update notes. Fees are paid upfront in cash without recourse. Edison may seek additional fees for the provision of roadshows and related IR services for the client but does not get remunerated for any investment banking services. We never take payment in stock, options or warrants for any of our services.

Accuracy of content: All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report and have not sought for this information to be independently verified. Opinions contained in this report represent those of the research department of Edison at the time of publication. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations.

Exclusion of Liability: To the fullest extent allowed by law, Edison shall not be liable for any direct, indirect or consequential losses, loss of profits, damages, costs or expenses incurred or suffered by you arising out or in connection with the access to, use of or reliance on any information contained on this note.

No personalised advice: The information that we provide should not be construed in any manner whatsoever as, personalised advice. Also, the information provided by us should not be construed by any subscriber or prospective subscriber as Edison’s solicitation to effect, or attempt to effect, any transaction in a security. The securities described in the report may not be eligible for sale in all jurisdictions or to certain categories of investors.

Investment in securities mentioned: Edison has a restrictive policy relating to personal dealing and conflicts of interest. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report, subject to Edison's policies on personal dealing and conflicts of interest.

Copyright: Copyright 2024 Edison Investment Research Limited (Edison).

Australia

Edison Investment Research Pty Ltd (Edison AU) is the Australian subsidiary of Edison. Edison AU is a Corporate Authorised Representative (1252501) of Crown Wealth Group Pty Ltd who holds an Australian Financial Services Licence (Number: 494274). This research is issued in Australia by Edison AU and any access to it, is intended only for "wholesale clients" within the meaning of the Corporations Act 2001 of Australia. Any advice given by Edison AU is general advice only and does not take into account your personal circumstances, needs or objectives. You should, before acting on this advice, consider the appropriateness of the advice, having regard to your objectives, financial situation and needs. If our advice relates to the acquisition, or possible acquisition, of a particular financial product you should read any relevant Product Disclosure Statement or like instrument.

New Zealand

The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are “wholesale clients” for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a “personalised service” and, to the extent that it contains any financial advice, is intended only as a “class service” provided by Edison within the meaning of the FAA (i.e. without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision.

United Kingdom

This document is prepared and provided by Edison for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA Rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research.

This Communication is being distributed in the United Kingdom and is directed only at (i) persons having professional experience in matters relating to investments, i.e. investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "FPO") (ii) high net-worth companies, unincorporated associations or other bodies within the meaning of Article 49 of the FPO and (iii) persons to whom it is otherwise lawful to distribute it. The investment or investment activity to which this document relates is available only to such persons. It is not intended that this document be distributed or passed on, directly or indirectly, to any other class of persons and in any event and under no circumstances should persons of any other description rely on or act upon the contents of this document.

This Communication is being supplied to you solely for your information and may not be reproduced by, further distributed to or published in whole or in part by, any other person.

United States

Edison relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. This report is a bona fide publication of general and regular circulation offering impersonal investment-related advice, not tailored to a specific investment portfolio or the needs of current and/or prospective subscribers. As such, Edison does not offer or provide personal advice and the research provided is for informational purposes only. No mention of a particular security in this report constitutes a recommendation to buy, sell or hold that or any security, or that any particular security, portfolio of securities, transaction or investment strategy is suitable for any specific person.

London │ New York │ Frankfurt

20 Red Lion Street

London, WC1R 4PS

United Kingdom

London │ New York │ Frankfurt

20 Red Lion Street

London, WC1R 4PS

United Kingdom

General disclaimer and copyright

This report has been commissioned by SIGA Technologies and prepared and issued by Edison, in consideration of a fee payable by SIGA Technologies. Edison Investment Research standard fees are £60,000 pa for the production and broad dissemination of a detailed note (Outlook) following by regular (typically quarterly) update notes. Fees are paid upfront in cash without recourse. Edison may seek additional fees for the provision of roadshows and related IR services for the client but does not get remunerated for any investment banking services. We never take payment in stock, options or warrants for any of our services.

Accuracy of content: All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report and have not sought for this information to be independently verified. Opinions contained in this report represent those of the research department of Edison at the time of publication. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations.

Exclusion of Liability: To the fullest extent allowed by law, Edison shall not be liable for any direct, indirect or consequential losses, loss of profits, damages, costs or expenses incurred or suffered by you arising out or in connection with the access to, use of or reliance on any information contained on this note.

No personalised advice: The information that we provide should not be construed in any manner whatsoever as, personalised advice. Also, the information provided by us should not be construed by any subscriber or prospective subscriber as Edison’s solicitation to effect, or attempt to effect, any transaction in a security. The securities described in the report may not be eligible for sale in all jurisdictions or to certain categories of investors.

Investment in securities mentioned: Edison has a restrictive policy relating to personal dealing and conflicts of interest. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report, subject to Edison's policies on personal dealing and conflicts of interest.

Copyright: Copyright 2024 Edison Investment Research Limited (Edison).

Australia

Edison Investment Research Pty Ltd (Edison AU) is the Australian subsidiary of Edison. Edison AU is a Corporate Authorised Representative (1252501) of Crown Wealth Group Pty Ltd who holds an Australian Financial Services Licence (Number: 494274). This research is issued in Australia by Edison AU and any access to it, is intended only for "wholesale clients" within the meaning of the Corporations Act 2001 of Australia. Any advice given by Edison AU is general advice only and does not take into account your personal circumstances, needs or objectives. You should, before acting on this advice, consider the appropriateness of the advice, having regard to your objectives, financial situation and needs. If our advice relates to the acquisition, or possible acquisition, of a particular financial product you should read any relevant Product Disclosure Statement or like instrument.

New Zealand

The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are “wholesale clients” for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a “personalised service” and, to the extent that it contains any financial advice, is intended only as a “class service” provided by Edison within the meaning of the FAA (i.e. without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision.

United Kingdom

This document is prepared and provided by Edison for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA Rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research.

This Communication is being distributed in the United Kingdom and is directed only at (i) persons having professional experience in matters relating to investments, i.e. investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "FPO") (ii) high net-worth companies, unincorporated associations or other bodies within the meaning of Article 49 of the FPO and (iii) persons to whom it is otherwise lawful to distribute it. The investment or investment activity to which this document relates is available only to such persons. It is not intended that this document be distributed or passed on, directly or indirectly, to any other class of persons and in any event and under no circumstances should persons of any other description rely on or act upon the contents of this document.

This Communication is being supplied to you solely for your information and may not be reproduced by, further distributed to or published in whole or in part by, any other person.

United States

Edison relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. This report is a bona fide publication of general and regular circulation offering impersonal investment-related advice, not tailored to a specific investment portfolio or the needs of current and/or prospective subscribers. As such, Edison does not offer or provide personal advice and the research provided is for informational purposes only. No mention of a particular security in this report constitutes a recommendation to buy, sell or hold that or any security, or that any particular security, portfolio of securities, transaction or investment strategy is suitable for any specific person.

London │ New York │ Frankfurt

20 Red Lion Street

London, WC1R 4PS

United Kingdom

London │ New York │ Frankfurt

20 Red Lion Street

London, WC1R 4PS

United Kingdom

More on SIGA Technologies

View All

Latest from the Healthcare sector

View All Healthcare content

Research: TMT

EML Payments — Sale of Sentenial agreed

EML Payments has agreed to sell Sentenial to GoCardless for an enterprise value of €32.75m/A$54.1m. As Sentenial is currently loss-making, the disposal will be earnings and cashflow accretive to EML in year one. Proceeds from the sale will be used to reduce debt and strengthen EML’s balance sheet. This disposal combined with the liquidation of PFS Card Services Ireland (PCSIL) leaves EML as a more focused group specialising in prepaid cards, with all remaining businesses profitable and cash generating.

Continue Reading

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free